synthetic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-05. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
=== Calibration materials === Calibration materials are compounds whose isotopic composition is known extremely well relative to the primary reference materials or which define the isotopic composition of the primary reference materials but are not the isotopic ratios to which data are reported in the scientific literature. For example, the calibration material IAEA-S-1 defines the isotopic scale for sulfur but measurements are reported relative to VCDT, not relative to IAEA-S-1. The calibration material serves the function of the primary reference material when the primary reference is exhausted, unavailable, or never existed in physical form.
==== Philippines ==== Think tanks in the Philippines could be generally categorized in terms of their linkages with the national government. Several were set up by the Philippine government for the specific purpose of providing research input into the policy-making process.
On January 4, 2008, the results of a mitochondrial DNA test, comparing the child's DNA with that of his potential grandmother, Clara de Rojas, were revealed by the Colombian government. It was reported that there was a very high probability that the boy was indeed part of the Rojas family. The same day, FARC released a communique in which they admitted that Emmanuel had been taken to Bogotá and "left in the care of honest persons" for safety reasons until a humanitarian exchange took place. The group accused President Uribe of "kidnapping" the child to sabotage his liberation. However, on January 10, 2008, FARC released Rojas and Gonzalez through a humanitarian commission headed by the International Committee of the Red Cross. On January 13, 2008, Venezuelan President Hugo Chávez stated his disapproval with the FARC strategy of armed struggle and kidnapping saying, "I don't agree with kidnapping and I don't agree with armed struggle". He repeated his call for a political solution and an end to the war in March and June 2008: "The guerrilla war is history...At this moment in Latin America, an armed guerrilla movement is out of place". In February 2008, FARC released four other political hostages "as a gesture of goodwill" toward Chávez, who had brokered the deal and sent Venezuelan helicopters with Red Cross logos into the Colombian jungle to pick up the freed hostages. On March 1, 2008, the Colombian armed forces launched a military operation 1.8 kilometres into Ecuador on a FARC position, killing 24, including Raúl Reyes, member of the FARC Central High Command.
"Tetrachlorodecaoxide" (TCDO) is a chlorite-containing substance with claimed immunomodulatory, macrophage-activating properties. WF10 (Macrokine, Immunokine, Oxoferin) is an aqueous solution of tetrachlorodecaoxide designed for intravenous injection. Tetrachlorodecaoxide/WF10 were originally developed by Oxo Chemie. The chemical formula is given as Cl4H2O114-. This incomplete formula shows a mixture of chlorite ion, water, and molecular oxygen: "Cl4H2O114-" = 4ClO2− + H2O + O2. Oxoferin was found to be equivalent with aqueous sodium chlorite. Tetrachlorodecaoxide / WF10 is used in the management of radiation cystitis, is effective in the treatment of diabetic foot ulcers, and is used in wound healing, where the mechanism of action is activation of the macrophage system, and increasing the partial pressure of oxygen in the wound.
Sources: en.wikipedia.org
=== Positions on trans identity, accusations of transphobia and connections to the far-right === On January 22, 2020, after a collage was posted in the city of Montpellier calling for the inclusion of trans women in the feminist movement with the slogan "sisters not cisTERF" (a pun on "cis", i.e. not trans, and "TERF", meaning "transgender-exclusionary radical feminist"), she commented she felt trans activism had become too important in the collage movement and within feminism on Twitter. She stated in particular that being a woman is a question of biology and that the activism of trans women was insulting and reduced women to a set of patriarchal stereotypes such as makeup and clothes. She denied trans women's womanhood, stating: "Throughout time, men have tried to silence women by silencing their revolts. Today, they do it from the inside by infiltrating our struggles". She refuses trans-inclusive language such as "people with vulvas". Her positions have led to her being considered a "TERF" by intersectional feminists. Following these statements, the Instagram account Collages Féminicides Paris distanced itself from her comments: "Discrimination has always been condemned […]. We're talking about the exclusion of a part of women from the struggle; transphobia is not a debate." She became increasingly marginalized in the collage movement, months after leaving its leadership. She was the subject of numerous insults on social networks, so much so that the collective reacted and specified that it repudiates any "killing rhetoric".
=== Terminology === Thermochemistry Chemical kinetics – the study of the rates of chemical reactions and investigates how different experimental conditions can influence the speed of a chemical reaction and yield information about the reaction's mechanism and transition states, as well as the construction of mathematical models that can describe the characteristics of a chemical reaction. Exothermic – a process or reaction in which the system releases energy to its surroundings in the form of heat. They are denoted by negative heat flow. Endothermic – a process or reaction in which the system absorbs energy from its surroundings in the form of heat. They are denoted by positive heat flow. Thermochemical equation Enthalpy change – internal energy of a system plus the product of pressure and volume. Its change in a system is equal to the heat brought to the system at constant pressure. Enthalpy of reaction Temperature – an objective comparative measure of heat. Calorimeter – an object used for calorimetry, or the process of measuring the heat of chemical reactions or physical changes as well as heat capacity. Heat – A form of energy associated with the kinetic energy of atoms or molecules and capable of being transmitted through solid and fluid media by conduction, through fluid media by convection, and through empty space by radiation. Joule – a unit of energy. Calorie Specific heat Specific heat capacity Latent heat Heat of fusion Heat of vaporization Collision theory Activation energy Activated complex Reaction rate Catalyst
Fischer (born 1979/1980), American chemist notable for work on the WE-CAN project and on peroxyacetyl nitrate Ernst Gottfried Fischer (1754–1831), German chemist who proposed a system of equivalents based on sulfuric acid equal to 1000 Ernst Otto Fischer (1918–2007), German chemist, 1973 Nobel Prize in Chemistry for pioneering work on organometallic chemistry Franz Joseph Emil Fischer (1877–1947), German chemist, co-discovered the Fischer–Tropsch process Hans Fischer (1881–1945), German organic chemist, 1930 Nobel Prize in Chemistry for research on the constitution of haemin and chlorophyll Nellie Ivy Fisher (1907–1995), London-born industrial chemist known for photographic chemistry Wilhelm Rudolph Fittig (1835–1910), German chemist, co-discovered Wurtz–Fittig reaction
=== Hyperparathyroidism === Lithium-associated hyperparathyroidism leads to hypercalcemia in about 4% of lithium-treated patients. Calcium levels should be checked for patients undergoing long-term lithium treatment. Chronically increased serum calcium can lead to kidney stones, osteoporosis, dyspepsia, hypertension, and renal impairment. Lithium may lead to exacerbation of pre-existing primary hyperparathyroidism or cause an increased set-point of calcium for parathyroid hormone suppression, leading to parathyroid hyperplasia.
The Morpholino drug eteplirsen, targeting exon 51 of the dystrophin mRNA, was approved as a human therapeutic by the FDA in 2016 and antisense oligonucleotides for Morpholinos targeting other exons are also subsequently approved. Morpholinos have been used in preclinical studies to inhibit replication of a broad range of viruses, including influenza, West Nile virus, SARS, hepatitis C, dengue fever, Ebola and Calicivirus, all of which are single stranded RNA viruses. They are in advanced development for prevention and treatment of Ebola and Marburg viruses. In March 2013, the Company announced positive results from a non-human primate study of AVI-7288, the drug candidate for treatment of Marburg virus infection. The results showed that intramuscular administration of AVI-7288 resulted in survival rates up to 100 percent in monkeys exposed to this fatal virus. These results are similar to those in previous studies when the drug was given by intravenous injection. In December 2019, golodirsen (Vyondys 53) received US FDA approval for the treatment of cases that can benefit from skipping exon 53 of the dystrophin transcript. The other approved PMO developed by Sarepta is casimersen (AMONDYS45) which is indicated for the treatment of DMD in patients amendable by exon 45 skipping. In addition to development of Morpholinos as therapeutics, AVI has conducted six human trials for colorectal and pancreatic cancers using their cancer vaccine AVICINE. In 2019, Sarepta signed a licensing agreement with Roche for the development, and commercialization outside of USA, for SRP-9001.
Sources: en.wikipedia.org
in vivo (of a scientific experiment or biological process) Occurring or made to occur inside the cells or tissues of a living organism; or, in the broadest sense, in any natural, unmanipulated setting. Contrast ex vivo and in vitro.
=== Breakthrough in talks === On the evening of 8 October 1972, at a secret meeting of Kissinger and Tho in a house in the Paris suburb of Gif-sur-Yvette once owned by the painter Fernand Léger, the decisive breakthrough in the talks came. Tho believed that Kissinger was, as he later put it, "in a rush" for a peace deal before the presidential election, and began with what he called "a very realistic and very simple proposal" for a ceasefire that would see the Americans pull all their forces out of Vietnam in exchange for the release of all the POWs in North Vietnam. As for the ultimate fate of South Vietnam, Tho proposed the creation of a "council of national reconciliation" that would govern the nation, but in the meantime, Thiệu could stay in power until the council was formed, while a "leopard's spot" ceasefire would come into effect with the Viet Cong and the Saigon government controlling whatever territories they were had at the time of the ceasefire. The "mutual withdrawal formula" was to be disregarded, with PAVN forces to stay in South Vietnam, with Tho giving Kissinger a vague promise that no more supplies would be sent down the Ho Chi Minh Trail. Kissinger accepted Tho's offer as the best deal possible, saying that the "mutual withdrawal formula" had to be abandoned, as it had been "unobtainable through ten years of war...We could not make it a condition for a final settlement. We had long passed that threshold".
Samples drawn from individuals with very high levels of bilirubin or lipids in their plasma (referred to as an icteric sample or a lipemic sample, respectively) may show falsely high readings for hemoglobin, because these substances change the colour and opacity of the sample, which interferes with hemoglobin measurement. This effect can be mitigated by replacing the plasma with saline. Some individuals produce an antibody that causes their platelets to form clumps when their blood is drawn into tubes containing EDTA, the anticoagulant typically used to collect CBC samples. Platelet clumps may be counted as single platelets by automated analyzers, leading to a falsely decreased platelet count. This can be avoided by using an alternative anticoagulant such as sodium citrate or heparin. Another antibody-mediated condition that can affect complete blood count results is red blood cell agglutination. This phenomenon causes red blood cells to clump together because of antibodies bound to the cell surface. Red blood cell aggregates are counted as single cells by the analyzer, leading to a markedly decreased red blood cell count and hematocrit, and markedly elevated MCV and MCHC (mean corpuscular hemoglobin concentration). Often, these antibodies are only active at room temperature (in which case they are called cold agglutinins), and the agglutination can be reversed by heating the sample to 37 °C (99 °F). Samples from people with warm autoimmune hemolytic anemia may exhibit red cell agglutination that does not resolve on warming.
Flesinoxan (developmental code name DU-29373) is a potent and selective 5-HT1A receptor partial or near-full agonist of the phenylpiperazine class. Originally developed as a potential antihypertensive drug, flesinoxan was later found to possess antidepressant and anxiolytic effects in animal tests. As a result, it was investigated in several small human pilot studies for the treatment of major depressive disorder, and was found to have robust effectiveness and very good tolerability. It was also developed for treatment of anxiety disorders. The drug reached phase 3 clinical trials for anxiety disorders. However, due to "management decisions", the development of flesinoxan was stopped and it was not pursued any further. In humans, flesinoxan enhances REM sleep latency, decreases body temperature, and increases ACTH, cortisol, prolactin, and growth hormone secretion. In addition, both flesinoxan and LY-178210 induce anxiety in humans.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.